Quickstart Highlights

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist (MC3R/MC4R) derived from Melanotan II^[1]. It was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women^[2]. Unlike PDE5 inhibitors, PT-141 acts centrally to enhance sexual desire by increasing dopamine release in brain reward and arousal regions^[3]. This educational protocol presents on-demand subcutaneous administration using a practical dilution for clear insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• FDA-approved dose: 1.75 mg (1750 mcg) at least 45 minutes before anticipated activity.
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the on-demand regimen.

• Goal: Support sexual desire and arousal through central melanocortin receptor activation^[3].
• Schedule: On-demand subcutaneous injection ≥45 minutes before anticipated activity.
• Dose: 1.75 mg (1750 mcg) per the FDA-approved regimen^[2].
• Limits: Maximum once per 24 hours; no more than 8 doses per month^[3].
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.

Dosing Protocol

Suggested on-demand approach.

• Standard Dose: 1.75 mg (53 units) subcutaneously.
• Timing: At least 45 minutes before anticipated sexual activity^[2].
• Frequency: No more than once every 24 hours.
• Monthly Limit: Maximum 8 injections per month^[3].
• Route: Subcutaneous (abdomen or thigh); rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[9].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container^[7].
• Rotate injection sites (abdomen, thighs) to reduce local irritation^[6].
• Inject slowly; wait a few seconds before withdrawing the needle.
• PT-141 may cause transient blood pressure elevation; avoid use in uncontrolled hypertension^[3].
• Nausea is the most common side effect; it is typically mild and transient^[3].

How This Works

Bremelanotide (PT-141) is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), acting as a non-selective melanocortin receptor agonist with predominant activity at MC3R and MC4R^[3]. In the central nervous system, MC4R activation leads to enhanced dopamine release in key brain reward and arousal regions—including the nucleus accumbens and medial preoptic area—which increases sexual motivation and desire^[3]. Unlike PDE5 inhibitors (e.g., sildenafil), PT-141 does not directly affect the nitric oxide pathway; in males, its pro-erectile effect is secondary to central mechanisms stimulating nitric oxide production in penile tissue^[3]. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation^[3].

Potential Benefits & Side Effects

Observations from clinical literature.

• Benefits: Clinical trials in premenopausal women with HSDD showed PT-141 significantly improves sexual desire scores (FSFI-Desire) and reduces distress (FSDS-DAO) versus placebo^[3].
• Early studies in men demonstrated improved erectile responses with intranasal PT-141^[1].
• Common Side Effects: Nausea (~40%), flushing (~20%), headache (~11%); these are typically mild and transient^[3].
• Other Effects: Transient blood pressure elevation, skin hyperpigmentation with repeated use^[3].
• Subcutaneous administration provides ~100% bioavailability and is better tolerated than intranasal delivery^[3].

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain open communication with partners about expectations and timing.
• Address underlying contributors to low desire (stress, relationship factors, hormonal status).
• Limit alcohol consumption, which may blunt response or worsen nausea.
• Ensure adequate sleep and stress management to support overall sexual health.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[7].

• Clean the vial stopper and skin with alcohol; allow to dry^[7].
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen, thighs) to avoid lipohypertrophy^[6].
• Discard needles and syringes after single use^[7].

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

References